Aileron, Roche deal

Aileron and Roche partnered to discover, develop and commercialize therapeutics against up to five undisclosed targets using Aileron's Stapled Peptide technology. The therapeutics will be developed for different therapeutic indications, including cancer, virology, inflammation, metabolism and CNS. Aileron will be responsible for the majority of discovery and preclinical testing, while Roche will be primarily responsible for further development. Aileron is eligible for at least $25 million in technology access fees and R&D support and also is eligible for $1.1 billion in milestones, plus royalties. ...